1
|
Graham MA, Askey H, Campbell AD, Chan L, Cooper KG, Cui Z, Dalgleish A, Dave D, Ensor G, Galan Espinosa MR, Hamilton P, Heffernan C, Jackson LV, Jing D, Jones MF, Liu P, Mulholland KR, Pervez M, Popadynec M, Randles E, Tomasi S, Wang S. Development and Scale-Up of an Improved Manufacturing Route to the ATR Inhibitor Ceralasertib. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00482] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Mark A. Graham
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Hannah Askey
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Andrew D. Campbell
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Lai Chan
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Katie G. Cooper
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Zhaoshan Cui
- Asymchem Laboratories (Tianjin) Co. Ltd., TEDA, Tianjin 300457, P. R. China
| | - Andrew Dalgleish
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - David Dave
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Gareth Ensor
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Maria Rita Galan Espinosa
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Peter Hamilton
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Claire Heffernan
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Lucinda V. Jackson
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Dajiang Jing
- Asymchem Laboratories (Tianjin) Co. Ltd., TEDA, Tianjin 300457, P. R. China
| | - Martin F. Jones
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Pengpeng Liu
- Asymchem Laboratories (Tianjin) Co. Ltd., TEDA, Tianjin 300457, P. R. China
| | - Keith R. Mulholland
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Mohammed Pervez
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Michael Popadynec
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Emma Randles
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Simone Tomasi
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Shenghua Wang
- Asymchem Laboratories (Tianjin) Co. Ltd., TEDA, Tianjin 300457, P. R. China
| |
Collapse
|